|
1
|
Gupta K, Miller JD, Li JZ, Russell MW and
Charbonneau C: Epidemiologic and socioeconomic burden of metastatic
renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev.
34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Peng J, Mo R, Ma J and Fan J: let-7b and
let-7c are determinants of intrinsic chemoresistance in renal cell
carcinoma. World J Surg Oncol. 13:1752015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nerich V, Hugues M, Paillard MJ, Borowski
L, Nai T, Stein U, Nguyen Tan Hon T, Montcuquet P, Maurina T,
Mouillet G, et al: Clinical impact of targeted therapies in
patients with metastatic clear-cell renal cell carcinoma. Onco
Targets Ther. 7:365–374. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang L, Williamson SR, Wang M, Davidson
DD, Zhang S, Baldridge LA, Du X and Cheng L: Molecular subtyping of
metastatic renal cell carcinoma: Implications for targeted therapy.
Mol Cancer. 13:392014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Youssef YM, White NM, Grigull J, Krizova
A, Samy C, Mejia-Guerrero S, Evans A and Yousef GM: Accurate
molecular classification of kidney cancer subtypes using microRNA
signature. Eur Urol. 59:721–730. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Motzer RJ and Russo P: Systemic therapy
for renal cell carcinoma. J Urol. 163:408–417. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kurozumi A, Kato M, Goto Y, Matsushita R,
Nishikawa R, Okato A, Fukumoto I, Ichikawa T and Seki N: Regulation
of the collagen cross-linking enzymes LOXL2 and PLOD2 by
tumor-suppressive microRNA-26a/b in renal cell carcinoma. Int J
Oncol. 48:1837–1846. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Coppin C, Kollmannsberger C, Le L,
Porzsolt F and Wilt TJ: Targeted therapy for advanced renal cell
cancer (RCC): A cochrane systematic review of published randomised
trials. BJU Int. 108:1556–1563. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zeng Y: Principles of micro-RNA production
and maturation. Oncogene. 25:6156–6162. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Carrington JC and Ambros V: Role of
microRNAs in plant and animal development. Science. 301:336–338.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Engels BM and Hutvagner G: Principles and
effects of microRNA-mediated post-transcriptional gene regulation.
Oncogene. 25:6163–6169. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Giannakakis A, Coukos G, Hatzigeorgiou A,
Sandaltzopoulos R and Zhang L: miRNA genetic alterations in human
cancers. Expert Opin Biol Ther. 7:1375–1386. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nelson KM and Weiss GJ: MicroRNAs and
cancer: Past, present and potential future. Mol Cancer Ther.
7:3655–3660. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Goto Y, Kurozumi A, Enokida H, Ichikawa T
and Seki N: Functional significance of aberrantly expressed
microRNAs in prostate cancer. Int J Urol. 22:242–252. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dias F, Teixeira AL, Santos JI, Gomes M,
Nogueira A, Assis J and Medeiros R: Renal cell carcinoma
development and miRNAs: A possible link to the EGFR pathway.
Pharmacogenomics. 14:1793–1803. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Z, Yu X, Shen J and Jiang Y: MicroRNA
dysregulation in uveal melanoma: A new player enters the game.
Oncotarget. 6:4562–4568. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lv C, Bai Z, Liu Z, Luo P and Zhang J:
MicroRNA-495 suppresses human renal cell carcinoma malignancy by
targeting SATB1. Am J Transl Res. 7:1992–1999. 2015.PubMed/NCBI
|
|
21
|
Zhang J, Liu D, Feng Z, Mao J, Zhang C, Lu
Y, Li J, Zhang Q, Li Q and Li L: MicroRNA-138 modulates metastasis
and EMT in breast cancer cells by targeting vimentin. Biomed
Pharmacother. 77:135–141. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun DK, Wang JM, Zhang P and Wang YQ:
MicroRNA-138 regulates metastatic potential of bladder cancer
through ZEB2. Cell Physiol Biochem. 37:2366–2374. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gao S, Wang J, Xie J, Zhang T and Dong P:
Role of miR-138 in the regulation of larynx carcinoma cell
metastases. Tumour Biol. Oct 24–2015.(Epub ahead of print).
|
|
24
|
Cristobal I, Torrejon B, González-Alonso
P, Manso R, Rojo F and García-Foncillas J: Downregulation of
miR-138 as a contributing mechanism to Lcn-2 overexpression in
colorectal cancer with liver metastasis. World J Surg.
40:1021–1022. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Long L, Huang G, Zhu H, Guo Y, Liu Y and
Huo J: Down-regulation of miR-138 promotes colorectal cancer
metastasis via directly targeting TWIST2. J Transl Med. 11:2752013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang H, Zhang H, Zhao M, Lv Z, Zhang X,
Qin X, Wang H, Wang S, Su J, Lv X, et al: MiR-138 inhibits tumor
growth through repression of EZH2 in non-small cell lung cancer.
Cell Physiol Biochem. 31:56–65. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Han L, Zhang G, Zhang N, Li H, Liu Y, Fu A
and Zheng Y: Prognostic potential of microRNA-138 and its target
mRNA PDK1 in sera for patients with non-small cell lung cancer. Med
Oncol. 31:1292014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu R, Zeng G, Gao J, Ren Y, Zhang Z, Zhang
Q, Zhao J, Tao H and Li D: miR-138 suppresses the proliferation of
oral squamous cell carcinoma cells by targeting Yes-associated
protein 1. Oncol Rep. 34:2171–2178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ma F, Zhang M, Gong W, Weng M and Quan Z:
MiR-138 suppresses cell proliferation by targeting bag-1 in
gallbladder carcinoma. PLoS One. 10:e01264992015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yu C, Wang M, Li Z, Xiao J, Peng F, Guo X,
Deng Y, Jiang J and Sun C: MicroRNA-138-5p regulates pancreatic
cancer cell growth through targeting FOXC1. Cell Oncol (Dordr).
38:173–181. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang B, Li H, Huang L, Luo C and Zhang Y:
Clinical significance of microRNA 138 and cyclin D3 in
hepatocellular carcinoma. J Surg Res. 193:718–723. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Qiu S, Huang D, Yin D, Li F, Li X, Kung HF
and Peng Y: Suppression of tumorigenicity by microRNA-138 through
inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma
multiforme. Biochim Biophys Acta. 1832:1697–1707. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ye XW, Yu H, Jin YK, Jing XT, Xu M, Wan ZF
and Zhang XY: miR-138 inhibits proliferation by targeting
3-phosphoinositide-dependent protein kinase-1 in non-small cell
lung cancer cells. Clin Respir J. 9:27–33. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Han LP, Fu T, Lin Y, Miao JL and Jiang QF:
MicroRNA-138 negatively regulates non-small cell lung cancer cells
through the interaction with cyclin D3. Tumour Biol. 37:291–298.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li J, Wang Q, Wen R, Liang J, Zhong X,
Yang W, Su D and Tang J: miR-138 inhibits cell proliferation and
reverses epithelial-mesenchymal transition in non-small cell lung
cancer cells by targeting GIT1 and SEMA4C. J Cell Mol Med.
19:2793–2805. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang W, Zhao LJ, Tan YX, Ren H and Qi ZT:
MiR-138 induces cell cycle arrest by targeting cyclin D3 in
hepatocellular carcinoma. Carcinogenesis. 33:1113–1120. 2012.
View Article : Google Scholar : PubMed/NCBI
|
